Epstein Secrets

fidentiality to S&P and its clients, according to case records. In March 2016, Pinto-Thomaz passed the inside information about the paint merger to Jeremy Millul, a friend, and to Abell Oujaddou, his hairdresser, so that they could "use it to make profitable trades in Valspar stock and options.," Berman said

regulators. But in 2017, the company practically beamed that it had "received clearance from the U.S. Food and Drug Administration for the Company's Investigational New Drug (IND) application lodged last month." The fact that Collins' role in the legislation could also have benefited other companies — and may even have been

s. 23 EFTA00069948 SDNY News Clips, Wednesday, July 31, 2019 In March 2016, Pinto-Thomaz passed the inside information about the paint merger to Jeremy Millul, a friend, and to Abell Oujaddou, his hairdresser, so that they could "use it to make profitable trades in Valspar stock and options.," Berman said

regulators. But in 2017, the company practically beamed that it had "received clearance from the U.S. Food and Drug Administration for the Company's Investigational New Drug (IND) application lodged last month." The fact that Collins' role in the legislation could also have benefited other companies — and may even have been

fidentiality to S&P and its clients, according to case records. In March 2016, Pinto-Thomaz passed the inside information about the paint merger to Jeremy Millul, a friend, and to Abell Oujaddou, his hairdresser, so that they could "use it to make profitable trades in Valspar stock and options.," Berman said

regulators. But in 2017, the company practically beamed that it had "received clearance from the U.S. Food and Drug Administration for the Company's Investigational New Drug (IND) application lodged last month." The fact that Collins' role in the legislation could also have benefited other companies — and may even have been